Table 1.
Baseline characteristics
| Items | TOCE | TOCE + HAIC | Provability | |
|---|---|---|---|---|
| n = 9 | n = 10 | |||
| Age (years) | Median | 81 | 72 | 0.22 |
| Range | 55–85 | 36–84 | ||
| Gender | Female | 2 | 5 | 0.09 |
| Male | 7 | 5 | ||
| Performance status | 0/1 | 8/1 | 10/0 | 0.47 |
| Etiology | HBV infection | 1 | 1 | 0.32 |
| HCV infection | 7 | 5 | ||
| Alcohol | 0 | 1 | ||
| NASH | 0 | 1 | ||
| Autoimmune hepatitis | 0 | 1 | ||
| Primary Biliary Cirrhosis | 0 | 1 | ||
| Unknown Etiology | 1 | 0 | ||
| Cirrhosis (Yes/No) | 9/0 | 10/0 | 1.00 | |
| Child-Pugh Grade | A/B/C | 8/1/0 | 7/3/0 | 0.36 |
| Size (mm) | Median | 22 | 21.5 | 0.87 |
| Range | 10–32 | 10–85 | ||
| Number | 1 | 0 | 1 | 0.41 |
| ≤3 | 4 | 1 | ||
| >3 | 5 | 8 | ||
| TNM | I/II/III | 0/3/6 | 0/5/5 | 0.55 |
| BCLC | 0/A/B/C/D | 0/3/6/0/0 | 0/2/8/0/0 | 0.65 |
| Previous Treatment | DDP-H | 8 | 7 | |
| TACE | 9 | 6 | 0.51 | |
TOCE, transarterial oily chemoembolization; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona-Clinic Liver Cancer staging classification